N. Cordua

Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer

A. Santoro, P. Zucali, F. De Vincenzo, 2020, Frontiers in Oncology.

Systemic treatments for thymic tumors: a narrative review

P. Zucali, F. De Vincenzo, M. Perrino, 2021, Mediastinum.

Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress

P. Zucali, F. De Vincenzo, M. Perrino, 2023, Frontiers in Immunology.

Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2‐B3) and thymic carcinoma previously treated with chemotherapy

A. Santoro, S. Bozzarelli, L. Giordano, 2021, Cancer.

Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial.

G. Giaccone, A. Santoro, V. Bagnardi, 2022, The Lancet. Oncology.

Prognostic Significance of Organ-Specific Metastases in Patients with Metastatic Upper Tract Urothelial Carcinoma

A. Giordano, A. Morrione, V. Nardone, 2022, Journal of Clinical Medicine.

Advances in drug treatments for mesothelioma

A. Santoro, P. Zucali, F. De Vincenzo, 2022, Expert opinion on pharmacotherapy.

High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients

G. Di Lorenzo, G. Peluso, C. Buonerba, 2018, Medicine.

A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.

A. Santoro, L. Giordano, P. Zucali, 2020, Lung cancer.

Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?

E. Giovannetti, G. Peters, R. Dziadziuszko, 2023, International journal of molecular sciences.

Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs

S. Della Bella, E. Voulaz, P. Zucali, 2024, Frontiers in immunology.

Thymic Epithelial Tumor and Immune System: The Role of Immunotherapy

P. Zucali, F. De Vincenzo, M. Perrino, 2023, Cancers.

New target therapies in prostate cancer: from radioligand therapy, to PARP-inhibitors and immunotherapy.

P. Zucali, F. De Vincenzo, M. Perrino, 2024, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....